SB-207499. Antiasthmatic/antiinflammatory phosphodiesterase IV inhibitor

Drugs of the Future

Volumn 23, Issue 6, 1998, Pages 607-615

  Silvestre, J ^a   Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 1 (2 METHOXYETHYL) 2(1H) PYRIDINONE; 4 CYANO 4 [3 CYCLOPENTYLOXY 4 METHOXY PHENYL] 1 CYCLOHEXANECARBOXYLIC ACID; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ATIZORAM; CILOMILAST; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYTOKINE; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PREDNISOLONE; ROLIPRAM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING SITE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0031871149     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.06.457488     Document Type: Review

References (49)

1. Christensen, S.B., Guider, A., Forster, C.J. et al. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 1998, 41: 821-35.
2. Christensen, S.B. (SmithKline Beecham Corp.). Cpds. useful for treating allergic and inflammatory diseases. EP 633776, JP 95508508, US 5552438, US 5602157, WO 9319749.
3. Bordas-Nagy, J., Gorycki, P., Webb, K.S. (SmithKline Beecham Corp.). Cyano cpds. and preparation thereof. JP 97510213, WO 9524381.
4. Bergman, M.R., Holygross, B.J. Pharmacological modulation of myocardial tumor necrosis factor α production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996, 279: 247-54.
5. Müller, T., Engels, P., Fozard, J.R. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol Sci 1996, 17: 294-8.
6. Semmler, J., Wachtel, H., Endres, S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993, 15: 409-13.
7. Teixeira, M.M., Gristwood, R.W., Cooper, N., Hellewell, P.G. Phosphodiesterase (PDE)4 inhibitors: Antiinflammatory drugs of the future? Trends Pharmacol Sci 1997, 18: 164-71.
8. Verghese, M.W., McConnell, R.T., Strickland, A.B., Gooding, R.C., Stimpson, S.A., Yarnall, D.P., Taylor, J.D., Furdon, P.J. Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995, 272: 1313-20.
9. Torphy, T.J., Christensen, S.B., Barnette, M.S., Burman, M., Cieslinski, L.B., DeWolf, W.E. Jr. Molecular basis for an improved therapeutic index of SB 207499, a second generation phosphodiesterase 4 inhibitor. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2042.
10. Barnette, M.S., Christensen, S.B., Essayan, D.M., Grous, M., Prabhakar, U., Rush, J.A., Kagey-Sobotka, A., Torphy, T.J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998, 284: 420-6.
11. Barnette, M.S., Christensen, S.B., Grous, M., Prabhakar, U., Rush, J.A., Essayan, D.M., Kagey-Sobotka, A., Torphy, T.J. Antiinflammatory actions of SB 207499, a novel second generation phosphodiesterase 4 inhibitor. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2044.
12. Barnette, M.S., Christensen, S.B., Essayan, D.M., Esser, K.M., Grous, M., Huang, S.-K., Manning, C.D., Prabhakar, U., Rush, J., Torphy, T.J. SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor, suppresses activities of several immune and inflammatory cells. Amer J Respir Crit Care Med 1994, 149: A209.
13. ™), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. Amer J Respir Crit Care Med 1998, 157: A827.
14. Underwood, D.C., Bochnowicz, S., Osborn, R., Hay, D., Gorycki, P.D., Christensen, S.B., Torphy, T.J. Anti-asthmatic potential of the second generation phosphodiesterase 4 inhibitor, SB 207499. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2045.
15. Griswold, D.E., Tzimas, M.N., Badger, A.M., Gorycki, P.D., Levandoski, P.A., Torphy, T.J. SB 207499, a second generation phosphodiesterase 4 inhibitor, reduces TNFα and IL-4 production in vivo. Annu Cong Eur Respir Soc (Sept 20-24, Berlin) 1997, Abst P2043.
16. ™), a second generation phosphodiesterase 4 inhibitor, suppresses the production of proinflammatory cytokines. Amer J Respir Crit Care Med 1998, 157: A828.
17. ™ (SB 207499), a novel & selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Amer J Respir Crit Care Med 1998, 157: A409.
18. ™), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Amer J Respir Crit Care Med 1998, 157: A413.
19. SB-207499 development status. SmithKline Beecham Company Communication 1998, May 7.
20. Chambers, R.J., Marfat, A., Cheng, J.B. et al. Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor-α. Bioorg Med Chem Lett 1997, 7: 739-44.
21. 3H]rolipram binding site. Bioorg Med Chem Lett 1995, 5: 1969-72.
22. Souness, J.E., Maslen, C., Webber, S., Foster, M., Raeburn, D., Palfreyman, M.N., Ashton, M.J., Karlsson, J.-A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclase AMP-specific phosphodiesterase: Comparison with rolipram. Brit J Pharmacol 1995, 115: 39-46.
23. Karlsson, J.-A., Souness, J., Webber, S., Pollock, K., Raeburn, D. Antiinflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401. Int Arch Allergy Immunol 1995, 107: 425-6.
24. Ashton, M.J., Cook, D.C., Fenton, G., Karlsson, J.-A., Palfreyman, M.N., Raeburn, D., Ratcliffe, A.J., Souness, J.E., Thurairatnam, S., Vicker, N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. Syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem 1994, 37: 1696-703.
25. Souness, J.E., Houghton, C., Sardar, N., Withnal, M.T. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Brit J Pharmacol 1997, 121: 743-50.
26. Buckle, D.R., Arch, J.R.S., Connolly, B.J., Fenwick, A.E., Foster, K.A., Murray, K.J., Readshaw, S.A., Smallridge, M., Smith, D.G. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem 1994, 37: 476-85.
27. Lowe, J.A. III, Archer, R.L., Chapin, D.S. et al. Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. J Med Chem 1991, 34: 624-8.
28. Hughes, B., Howat, D., Lisle, H. et al. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Brit J Pharmacol 1996, 118: 1183-91.
29. Heaslip, R.J., Lombardo, L.J., Golankiewicz, J.M., Ilsemann, B.A., Evans, D.Y., Sickels, B.D., Mudrick, J.K., Bagli, J., Weichman, B.M. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther 1994, 268: 888-96.
30. Boichot, E., Germain, N., Lugnier, C., Lagente, V., Bourguignon, J.-J. In vitro anti-inflammatory activities of a new serie of selective phosphodiesterase 4 inhibitors derived of 9-benzyladenines. Amer J Respir Crit Care Med 1998, 157: A141.
31. Escott, K.J., Birrell, M., Webber, S.E., Souness, J.E., Geiger, L.E., Aldous, D., Sargent, C.A. Efficacy versus toxicity of PDE4 inhibitors. Amer J Respir Crit Care Med 1998, 157: A413.
32. Cavalla, D., Gale, D.D., Spina, D., Seeds, E., Banner, K., Page, C.P., Wong, R.H., Jordan, S., Burch, R.M., Chasin, M. Activity of V11294A, a novel phosphodiesterase 4 (PDE4) inhibitor, in cellular and animal models of asthma. Amer J Respir Crit Care Med 1997, 155: A660.
33. Cohan, V.L., Showell, H.J., Fisher, D.A., Pazoles, C.J., Watson, J.W., Turner, C.R., Cheng, J.B. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J Pharmacol Exp Ther 1996, 278: 1356-61.
34. Yamashima, S., Wada, K., Kaminuma, O., Yoshikawa, H., Ikezawa, I. Inhibitory effects of T-440, a novel antiasthmatic agent, on phosphodiesterase activity and eosinophil function in guinea pigs. Jpn J Allergol 1995, 44(8): Abst 301.
35. Iwasaki, T., Kondo, K., Kuroda, T., Moritani, Y., Yamagata, S., Sugiura, M., Kikkawa, K., Kaminuma, O., Ikezawa, K. Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. J Med Chem 1996, 39: 2696-704.
36. Hughes, B., Owens, R., Perry, M., Warrellow, G., Allen, R. PDE4 inhibitors: The use of molecular cloning in the design and development of novel drugs. Drugs Discov Today 1997, 2: 89-101.
37. Brackeen, M.F., Cowan, D.J., Stafford, J.A., Schoenen, F.J., Veal, J.M., Domanico, P.L., Rose, D., Strickland, A.B., Verghese, M., Feldman, P.L. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase. J Med Chem 1995, 38: 4848-54.
38. Stafford, J.A., Veal, J.M., Feldman, P.L. et al. Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(±)-methyl-3-acetyl-4-[3-(cyclopentyloxy)-4- methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase. J Med Chem 1995, 38: 4972-5.
39. Molnar-Kimber, K.L., Yonno, L., Rhoad, A., Weichman, B.M., Heaslip, R.J. Inhibition of tumor necrosis factor a secretion from endotoxin stimulated human monocytes by WAY-PDA-641 and rolipram. J Immunol 1993, 150(8, Pt 2): Abst 1685.
40. Banner, K.H., Moriggi, E., Da Ros, B., Schioppacassi, G., Semeraro, C., Page, C.P. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Brit J Pharmacol 1996, 119: 1255-61.
41. Underwood, D.C., Osborn, R.R., Novak, L.B., Matthews, J.K., Newsholme, S.J., Undem, B.J., Hand, J.M., Torphy, T.J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993, 266: 306-13.
42. Underwood, D.C., Kotzer, C.J., Bochnowicz, S., Osborn, R.R., Luttman, M.A., Hay, D.W.P., Torphy, T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitor on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1994, 270: 250-9.
43. Raeburn, D., Underwood, S.L., Lewis, S.A. et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Brit J Pharmacol 1994, 113: 1423-31.
44. Wright, K.F., Turner, C.R., Jayasinghe-Beck, R., Cohan, V.L., Cheng, J.B., Watson, J.W. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor. Can J Physiol Pharmacol 1997, 75: 1001-8.
45. Spina, D., Ferlenga, P., Biasini, I., Moriggi, E., Marchini, F., Semeraro, C., Page, C.P. The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci 1998, 62: 953-65.
46. Holbrook, M., Gozzard, N., James, T., Higgs, G., Hughes, B. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Brit J Pharmacol 1996, 118: 1192-200.
47. Turner, C.R., Cohan, V.L., Cheng, J.B., Showell, H.J., Pazoles, C.J., Watson, J.W. The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther 1996, 278: 1349-55.
48. Kaminuma, O., Kikkawa, H., Matsubra, S., Ikezawa, K. Inhibitory effect of a novel phosphodiesterase IV inhibitor, T-440, on antigen-and chemical mediator-induced bronchoconstrictions in guinea pigs in vivo. Jpn J Pharmacol 1996, 72: 1-8.
49. Engels, P., Sullivan, M., Müller, T., Lübbert, H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE-IV-C). FEBS Lett 1995, 358: 305-10.